NCT06397001CompletedPhase 1
Treatment of AA Amyloidosis
An Open-label Single Center, Single Patient Study of an Experimental Antisense Oligonucleotide (ASO) Treatment in AA Amyloidosis
Source: ClinicalTrials.gov · Last updated 19 Feb 2025
Brief summary (registry, in English)
The purpose of this study is to assess the safety and efficacy of a subcutaneous injection of nL-SAA1-01in a patient with AA Amyloidosis.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (actual)
- First submitted
- 30 Apr 2024
- Start date
- 28 Nov 2023
- Primary completion date
- 2 Dec 2024
- Lead sponsor
- Nelson Leung, MD
- Diseases
- Amyloidosis
- NCT number
- NCT06397001
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 1
- From 28 Nov 2023 to the primary completion date, 2 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participant has any condition that in the opinion of the site investigator, would ultimately prevent the completion of study procedures
Who the study is looking for
- Biopsy proven AA amyloidosis
- Measurable disease
- Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.